Pharnext is the first European SME to focus on developing combinations of already approved drugs for novel therapeutic indications. It targets neuro-immunological pathologies with an initial emphasis on orphan diseases. The company has led an assertive program of expansion and opting for a large outsourcing policy. Pharnext is recruiting a staff of 15 and has been founded by experienced and renowned leaders of Genomics and European biotechnology. Pharnext took part in the Genome Informatics and Computational Biology Program which supports research in computational biology that will enable the development of tools for sequence analysis, gene mapping, complex trait mapping and genetic variation. These tools include mathematical and statistical methods for the identification of functional elements in complex genomes, the identification of patterns in large datasets, and the mapping of complex traits and genetic variations (SNPs).

The basic role of Pharnext in the project is the development of Genomic Microarrays of HLA typing. Pharnext will work on the technical R&D of genomic microarrays of HLA typing.